Tracy L. Hagemann, PhD
Position title: Associate Research Professor
PhD, Rush University
Contact Information
Waisman Center, Room 713A
1500 Highland Avenue
Madison, WI 53705
608-263-9192
tlhagemann@wisc.edu
Alexander Disease Research
Research Statement
Our research focuses on the role of astrocytes in neurodegenerative disease and the cellular consequences of their dysfunction. Astrocytes have traditionally been thought of as support cells that maintain ion and neurotransmitter homeostasis in the central nervous system (CNS). However, research over the past few decades has revealed more complex functions including the regulation of neurogenesis, synaptogenesis, neurotransmission and remyelination. In addition, astrocytes control blood flow, maintain the blood brain barrier, and contribute to the distribution and clearance of compounds through the CNS glymphatic system.
Astrocytes take on another critical role of reacting to CNS injury by activating anti-stress and neuroinflammatory pathways in both acute insults and chronic disease. Reactive astrocytes are heterogeneous in their response and can either promote or prevent regeneration and repair. Given the complexities of astrocyte function in the healthy CNS and their sometimes paradoxical role in brain and spinal cord injury, it can be difficult to dissect the effects of astrogliosis on other neural cell types from the primary insult.
To better understand astrocyte function in neurodegenerative disease, we have focused on one of the few examples of a primary disorder of astrocytes, Alexander disease. Alexander disease (AxD) is caused by mutations in the gene for glial fibrillary acidic protein (GFAP), an astrocyte specific intermediate filament protein, that lead to protein aggregation, activation of stress response genes, including GFAP, and reactive gliosis. AxD can affect all ages but is most severe in children, who often present with seizures, motor and cognitive delay, and a general failure to thrive. We have generated several rodent models with missense mutations homologous to those found in patients with the disease. These models allow us to study the effects of astrocyte dysfunction on other cell types in the mammalian CNS, including neurons and oligodendrocytes and their progenitors. As with other injuries, the astrocyte response to mutant GFAP is also heterogeneous, and a second goal is to identify the molecular networks controlling regional differences in astrocyte reactivity. Finally we hope that understanding the mechanisms behind Alexander disease pathology will lead to therapeutic strategies for this devastating disorder as well as other diseases with astropathology.
Selected Publications
-
Stowe, N. A., Singh, A. P., Barnett, B. R., Yi, S. Y., Frautschi, P. C., Messing, A., Hagemann, T. L., & Yu, J. J. (2024). Quantitative diffusion imaging and genotype-by-sex interactions in a rat model of Alexander disease. Magnetic resonance in medicine, 91(3), 1087–1098. https://doi.org/10.1002/mrm.29917
-
Gammie, S. C., Messing, A., Hill, M. A., Kelm-Nelson, C. A., & Hagemann, T. L. (2024). Large-scale gene expression changes in APP/PSEN1 and GFAP mutation models exhibit high congruence with Alzheimer’s disease. PloS one, 19(1), e0291995. https://doi.org/10.1371/journal.pone.0291995
-
Wang, L., Bukhari, H., Kong, L., Hagemann, T. L., Zhang, S. C., Messing, A., & Feany, M. B. (2022). Anastasis Drives Senescence and Non-Cell Autonomous Neurodegeneration in the Astrogliopathy Alexander Disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 42(12), 2584–2597. https://doi.org/10.1523/JNEUROSCI.1659-21.2021
-
Hagemann T. L. (2022). Alexander disease: models, mechanisms, and medicine. Current opinion in neurobiology, 72, 140–147. https://doi.org/10.1016/j.conb.2021.10.002
-
Hagemann, T. L., Powers, B., Lin, N. H., Mohamed, A. F., Dague, K. L., Hannah, S. C., Bachmann, G., Mazur, C., Rigo, F., Olsen, A. L., Feany, M. B., Perng, M. D., Berman, R. F., & Messing, A. (2021). Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment. Science translational medicine, 13(620), eabg4711. https://doi.org/10.1126/scitranslmed.abg4711
-
Boyd, M. M., Litscher, S. J., Seitz, L. L., Messing, A., Hagemann, T. L., & Collier, L. S. (2021). Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypes. Journal of neuroinflammation, 18(1), 67. https://doi.org/10.1186/s12974-021-02118-x
-
Helman G, Takanohashi A, Hagemann TL, Perng MD, Walkiewicz M, Woidill S, Sase S, Cross Z, Du Y, Zhao L, Waldman A, Haake BC, Fatemi A, Brenner M, Sherbini O, Messing A, Vanderver A, Simons C. (2020). Type II Alexander disease caused by splicing errors and aberrant overexpression of an uncharacterized GFAP isoform. Human Mutation, 41(6), 1131. https://doi.org/10.1002/humu.24008
-
Wang, L., Xia, J., Li, J., Hagemann, T. L., Jones, J. R., Fraenkel, E., Weitz, D. A., Zhang, S. C., Messing, A., & Feany, M. B. (2018). Tissue and cellular rigidity and mechanosensitive signaling activation in Alexander disease. Nature communications, 9(1), 1899. https://doi.org/10.1038/s41467-018-04269-7
-
Hagemann TL, Powers B, Mazur C, Kim A, Wheeler S, Hung G, Swayze E, Messing A. (2018). Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease. Annals of Neurology, 83(1):27-39. doi: 10.1002/ana.25118.
-
Wang L, Hagemann TL, Messing A, Feany MB. (2016) An In Vivo Pharmacological Screen Identifies Cholinergic Signaling as a Therapeutic Target in Glial-Based Nervous System Disease. Journal of Neuroscience. 3;36(5):1445-55. doi: 10.1523/JNEUROSCI.0256-15.2016.
-
Wang L, Hagemann TL, Kalwa H, Michel T, Messing A, Feany MB. (2015) Nitric oxide mediates glial-induced neurodegeneration in Alexander disease. Nature Communications. 26;6:8966. doi: 10.1038/ncomms9966.
-
Cotrina ML, Chen M, Han X, Iliff J, Ren Z, Sun W, Hagemann T, Goldman J, Messing A, Nedergaard M. (2014) Effects of traumatic brain injury on reactive astrogliosis and seizures in mouse models of Alexander disease. Brain Research. 25;1582:211-9. doi: 10.1016/j.brainres.2014.07.029.
-
Chen MH, Hagemann TL, Quinlan RA, Messing A, Perng MD. (2013) Caspase cleavage of GFAP produces an assembly-compromised proteolytic fragment that promotes filament aggregation. ASN Neuro. 19;5(5):e00125. doi: 10.1042/AN20130032.
-
Jany PL, Hagemann TL, Messing A. (2013) GFAP expression as an indicator of disease severity in mouse models of Alexander disease. ASN Neuro. 5(1):e00109.
-
Hagemann TL, Paylor R, Messing A. (2013) Deficits in adult neurogenesis, contextual fear conditioning, and spatial learning in a Gfap mutant mouse model of Alexander disease. Journal of Neuroscience. 20;33(47):18698-706. doi: 10.1523/JNEUROSCI.3693-13.2013.
-
Lapash Daniels CM, Austin EV, Rockney DE, Jacka EM, Hagemann TL, Johnson DA, Johnson JA, Messing A. (2012) Beneficial effects of nrf2 overexpression in a mouse model of alexander disease. Journal of Neuroscience. Aug 1;32(31):10507-15.
-
Toops KA, Hagemann TL, Messing A, Nickells RW. (2012) The effect of glial fibrillary acidic protein expression on neurite outgrowth from retinal explants in a permissive environment. BMC Research Notes. Dec 22;5:693.
-
Hagemann TL, Jobe EM, Messing A. (2012) Genetic ablation of Nrf2/antioxidant response pathway in Alexander disease mice reduces hippocampal gliosis but does not impact survival. PLoS One. 7(5):e37304.
-
Cengiz P, Kleman N, Uluc K, Kendigelen P, Hagemann T, Akture E, Messing A, Ferrazzano P, Sun D. (2011) Inhibition of Na+/H+ exchanger isoform 1 is neuroprotective in neonatal hypoxic ischemic brain injury. Antioxidants & Redox Signaling. 14(10):1803-13.
-
Messing A, LaPash Daniels CM, Hagemann TL. (2010) Strategies for treatment in Alexander disease. Neurotherapeutics. 7(4):507-15. doi: 10.1016/j.nurt.2010.05.013.
-
Cho W, Hagemann TL, Johnson DA, Johnson JA, Messing A. (2009) Dual transgenic reporter mice as a tool for monitoring expression of glial fibrillary acidic protein. Journal of Neurochemistry. Jul;110(1):343-51.
-
Hagemann, T. L., Boelens, W. C., Wawrousek, E. F., & Messing, A. (2009). Suppression of GFAP toxicity by alphaB-crystallin in mouse models of Alexander disease. Human molecular genetics, 18(7), 1190–1199. https://doi.org/10.1093/hmg/ddp013